Sabby Management’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Sabby Management’s Portfolio OTLKW Stock Details OTLKW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-177,439	Closed	-$27K	–	145
2018 Q4	$27K	Buy	+177,439	New	+$22.4K	0.01%	106

Other funds holding OTLKW

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Sabby Management's OTLKW Position: Q1 2019 in Review

Sabby Management sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2019, closing a stake of 177,439 shares — an estimated $27K sold.

Sabby Management first reported a position in OTLKW in Q4 2018 and held it in 1 quarter. The position peaked at $27K in Q4 2018. 6 funds tracked by Wall St. Rank hold OTLKW as of Q1 2019.

Sabby Management reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2019 after selling out during the quarter.
Sabby Management sold 177,439 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2019, an estimated $27K.
Sabby Management first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 1 quarter.
Sabby Management's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $27K in Q4 2018.
6 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.